NCT01540682View on ClinicalTrials.gov

MLN8237 in Head and Neck Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

November 30, 2015

Conditions
Head and Neck Cancer
Interventions
DRUG

MLN8237

Three dose levels of MLN8237 are planned:30, 40 and 50 mg po bid.

DRUG

Cetuximab

\~ 1 week prior to the initiation of radiation therapy and continuing for a grand total of 12 weeks.

RADIATION

Radiotherapy

Radiotherapy will be administered in 2-Gy fractions, 5 days a week to a total dose of \~70 Gy.

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT01540682 - MLN8237 in Head and Neck Cancer | Biotech Hunter | Biotech Hunter